1. Home >
  2. Export Import News >
  3. Business News >
  4. Alkem Laboratories Rating: Correction has factored in concerns on Daman >
  5. Alkem Laboratories Rating: Correction has factored in concerns on Daman

Online Export Import Data Search

Recent Searches: No Recent Searches
Complete Training Video : Click Here

Alkem Laboratories Rating: Correction has factored in concerns on Daman.

Date: 01-05-2018
Subject: Alkem Laboratories Rating: Correction has factored in concerns on Daman
The Daman inspection outcome remains a concern. We factor in lower US sales to factor in delayed approvals and, accordingly, reduce EPS estimates for FY19F and FY20F by 13% and 9%, respectively. We reset our 12-month price target at Rs 2,089/sh (down from Rs 2,298/sh) based on 22.5x FY20F EPS (methodology unchanged). Our target price implies 17% potential upside from current levels. Hence, we upgrade to Buy.

The domestic formulation business is a significant contributor to earnings and valuations. Alkem’s domestic business contributes 87-93% of Ebitda over FY18-20F. Alkem has sustained growth ahead of the broader market over the past four years despite higher dependence of acute segments and impact of price control. On a lower base of FY18F, we expect Alkem to record 14% CAGR over FY18-20F. Assuming 4x FY19F sales, the domestic business contributes 88% to our target price, in our assessment.
Since the Daman inspection, Alkem stock has lost Rs 400 mn in market cap, 2x its current US sales. We think the stock correction factors in delay in approvals and high possibility of a warning letter. In case of a warning letter, we expect 7% cut in earnings in FY20F. We don’t expect escalation into an import alert, which can adversely impact FY20F earnings by 18%.

Alkem is trading at 23.6x FY19F and 19.2x FY20F EPS estimates. The valuations are at 4%/10% premium to peers. We expect premium valuation for Alkem due to significant high contribution from India business and scope for Ebitda margins to expand beyond FY20F. As capex intensity reduces, free cash flow is likely to rise. The stock trades at FY20F FCF yield of 4%.

Concerns remain on the Daman formulation site

ALKEM stock has corrected 11% (vs. Sensex +4.3%) since the issuance of Form 483 at the Daman formulation site on 27 March 2018. We expect uncertainty around the inspection outcome may remain over the next 3-6 months. As per the new procedure followed by USFDA, the agency strives to communicate the inspection classification – OAI (Official Action Indicated), VAI (Voluntary Action Indicated) or NAI (No Action Indicated) – to the facility owner within 90 days. In the case of OAI, enforcement action in the form of a warning letter or an import alert is expected to be initiated within six months of inspection.

India business should sustain growth ahead of broader market

Over FY14-18F, Alkem recorded CAGR of 11.8% vs. industry growth of 10.6%, as per AIOCD data. Strong execution has a key role to play in outperformance vs. the broader market. We expect this to be sustained for the following reasons:

We expect the management to continue focus on execution. We don’t expect ceiling price revision or expansion of price control list in any material way till FY22F.
Scope to expand market presence, particularly in chronic therapy areas.
Geographic expansion is a possibility. Alkem has stronger presence in East India and is consistently trying to expand presence in other geographies.
Expansion in OTC segment and pursuing in-licensing deals.

Source: financialexpress.com

Get Sample Now

Which service(s) are you interested in?
 Export Data
 Import Data
 Exim Help

What is New?

Date: 24-01-2020
Notification No. 01/2020-Customs (ADD)
seeks to amend notification No. 40/2017-Customs(ADD) dated 25-08-2017, to revise anti-dumping duty on imports of "Sodium Nitrite" originating in or exported from China PR, in pursuance of final findings of sunset review investigations issued by DGTR vide notification No. 15/06/2016-DGTR dated the 8th November 2019..

Date: 23-01-2020
A.P. (DIR Series) Circular No.20
Merchanting Trade Transactions (MTT) – Revised Guidelines

Date: 23-01-2020
A.P. (DIR Series) Circular No.19
‘Voluntary Retention Route’ (VRR) for Foreign Portfolio Investors (FPIs) investment in debt – relaxations

Date: 23-01-2020
A.P. (DIR Series) Circular No.18
Investment by Foreign Portfolio Investors (FPI) in Debt

Date: 21-01-2020
Circular No. 4/2020 – Customs
Clarification relating to import of gifts - Reg

Date: 20-01-2020
A.P. (DIR Series) Circular No.17
Introduction of Rupee derivatives at International Financial Services Centres (IFSC)

Date: 17-01-2020
TRADE NOTICE NO. 46/2019-20
Mis-classification goods under 'Others' category at the time of Import- reg.

Date: 16-01-2020
Notification No.05/2020 - Customs (N.T.)
Exchange Rates Notification No.05/2020-Custom (NT) dated 16.01.2020.

Date: 15-01-2020
Notification No. 03/2020- Customs (N.T.)
Notification of Ghasuapara LCS for imports also by amendment of Notification No. 63/1994-Customs dated 21st November 1994

Date: 15-01-2020
Notification No. 04/2020-CUSTOMS (N.T.)
Tariff Notification in respect of Fixation of Tariff Value of Edible Oils, Brass Scrap, Poppy Seed, Areca nut, Gold & Silver - reg.

Exim Guru Copyright © 1999-2020 Exim Guru. All Rights Reserved.
The information presented on the site is believed to be accurate. However, InfodriveIndia takes no legal responsibilities for the validity of the information.
Please read our Terms of Use and Privacy Policy before you use this Export Import Data Directory.


C/o Infodrive India
E-2, 3rd Floor, Kalkaji Main Road
New Delhi - 110019, India
Phone : 011 - 40703001